The only therapeutic option for targeting CCN2 that has been studied in BM diseases, is the use of the humanized monoclonal anti-CCN2 antibody FG-3019 (Pamrevlumab), which, in combination with conventional chemotherapy, significantly prolonged the survival of mice injected with a primary xenograft of B-ALL cells (Lu et al. 2014). This evidence concerns the gene CCN2 and acute lymphoblastic leukemia.